Retatrutide, a novel dual stimulator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is exhibiting promising data in initial clinical trials . Ongoing inquiry implies https://bookmark-media.com/story21484012/retatrutide-emerging-studies-and-potential-medical-uses